journalsJournal
Nature Reviews Clinical Oncology
aka Nat Rev Clin Oncol
Commissioned clinical reviews for oncologists: treatment landscapes, biomarker strategies and trial-design critique, with the highest impact factor of any oncology journal.
Monthly review-only journal (launched 2004 as Nature Clinical Practice Oncology, renamed 2009). Publishes reviews and Perspectives on treatment paradigms, drug classes such as ADCs and bispecifics, trial methodology and health policy, plus Year in Review pieces. Does not carry primary trials.
Publisher
Springer Nature
Scope
clinical oncology
Website
Founded
2004
ISSN
1759-4774
Impact factor (2023)
81.1 · Clarivate Journal Citation Reports 2024 (2023 JIF)
Alan Ashworth
President, UCSF Helen Diller Family Comprehensive Cancer Center
DNA repairSynthetic lethalityBRCA
Co-discovered that BRCA-deficient cancers die when PARP is blocked, the idea behind an entire drug class.
Klaus Pantel
Director, Institute of Tumor Biology, UKE Hamburg
Liquid biopsyCirculating tumour cellsMinimal residual disease
Klaus Pantel is a pioneer of circulating tumour cell research and the liquid biopsy field.
Nothing links here yet.